EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® ...
GlobalData on MSN1d
Teva and Alvotech launch ustekinumab biosimilar injection in USTeva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...
Regulatory ApprovalFormycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CESTThe issuer is solely ...
GlobalData on MSN1d
Sanofi and Teva report new outcomes from Phase IIb trial of duvakitugSanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...
Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who ...
New research by Teva Pharmaceuticals Europe shows that 46% of generic medicines from the EU Critical List of Medicines are supplied by only one provider. This ...
Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a ...
Growth stocks can help to supercharge your investment portfolio and boost your retirement fund. The key, however, is to ...
but a US appeals court in 2020 reinstated the $235 million judgment against the generics manufacturer. Fast forward to February of this year, and the US Court of Appeals declined Teva's request to ...
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...
Teva's challenge Although Teva is known as the world’s largest generics manufacturer, it also has a branded drugs business and Copaxone is its largest single source of revenue. The latest news ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback